Amarin: IP Protection For VAZKEPA In Europe Now Extended Into 2039 - Quick Facts

(RTTNews) - Amarin Corporation plc (AMRN) announced it received a Decision to Grant from the European Patent Office for a new patent covering VAZKEPA that will extend VAZKEPA exclusivity eight additional years into 2039. Also, the company recently achieved success defending a separate European VAZKEPA patent from third-party opposition within the EPO.

Patrick Holt, President & CEO, Amarin, said: "Moving forward, we will continue to rigorously defend our IP rights and explore any possibilities to strengthen Amarin's patents and patent families around the world."

For More Such Health News, visit rttnews.com.